Analysis of circulating tumor DNA (ctDNA) from the phase II...

Annals of Oncology 2020 / 09 Vol. 31

Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy

Siefker-Radtke, A.O., Loriot, Y., Necchi, A., Huddart, R.A., Burgess, E.F., Rezazadeh, A., O'Hagan, A., De Porre, P., Avadhani, A., Monga, M., Cherkas, Y., Moy, C.H., Santiago-Walker, A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.823
Date:
September, 2020
File:
PDF, 79 KB
2020
Conversion to is in progress
Conversion to is failed